Petros Pharmaceuticals, Inc. announced it has partnered with a leading Contract Development and Manufacturing Organization (CDMO), for commercial production of STENDRA (avanafil) tablets. The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the product to the United States, and is expected to provide both cost savings and increase in gross margin.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4226 USD | -0.73% |
|
-1.03% | -70.03% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.03% | 2.98M | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- PTPI Stock
- News Petros Pharmaceuticals, Inc.
- Petros Pharmaceuticals, Inc. Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ to the United States